Definition, Etiology & Pathophysiology

Question	Answer
1. What is the clinical definition of Chronic Suppurative Lung Disease (CSLD) and how does it differ from Bronchiectasis?	CSLD is a clinical syndrome characterized by a daily moist/productive cough persisting for $>8\text{ weeks}$, with or without other features of suppurative lung disease, in the absence of high-resolution CT evidence of irreversible bronchial dilatation. Bronchiectasis is an anatomical diagnosis defined by permanent, irreversible, abnormal dilatation and distortion of one or more bronchi, usually demonstrated on HRCT of the chest. CSLD is often considered the precursor stage to established bronchiectasis.
2. What is Cole's "Vicious Cycle" hypothesis in the pathogenesis of bronchiectasis?	Cole's hypothesis explains progressive airway destruction via four interacting pillars: 1) Initial trigger (e.g., severe necrotizing pneumonia, foreign body, or genetic mucus defect); 2) Impaired mucociliary clearance and mucus retention; 3) Chronic bacterial colonization (e.g., H. influenzae, P. aeruginosa); and 4) Chronic, transmural, neutrophil-dominated airway inflammation. Release of neutrophil elastase, matrix metalloproteinases (MMPs), and reactive oxygen species destroys bronchial elastic lamina, cartilage, and smooth muscle, leading to irreversible bronchial dilatation.
3. What are the leading causes of pediatric bronchiectasis in resource-rich vs resource-limited settings?	In resource-rich settings, the predominant etiology is genetic/inherited disease, led by Cystic Fibrosis (CF), followed by Primary Ciliary Dyskinesia (PCD) and primary immunodeficiencies. In developing countries like India, post-infectious sequelae remain the most common etiology (post-measles, post-pertussis, post-tubercular, and severe adenoviral/staphylococcal necrotizing pneumonia), followed closely by Cystic Fibrosis (frequently underdiagnosed) and retained endobronchial foreign bodies.
4. What are the three morphological types of bronchiectasis described by Lynne Reid?	1) Cylindrical (Tubular) Bronchiectasis: Uniform, smooth dilatation of bronchi with preserved regular branching; most common and least severe. 2) Varicose Bronchiectasis: Irregular, alternating areas of bronchial dilatation and constriction resembling varicose veins, caused by localized mural scarring. 3) Cystic (Saccular) Bronchiectasis: Severe ballooning of bronchi ending in blind, fluid- or pus-filled sacs lacking bronchial tree continuation; carries the highest risk of massive hemoptysis and cor pulmonale.
5. VIVA TRAP: Can bronchiectasis ever be reversible?	Examiner: "Candidate, you defined bronchiectasis as irreversible. Can bronchial dilatation ever resolve?" Response: "Yes, sir/ma'am. Cylindrical bronchial dilatation that develops acutely following severe atelectasis, pertussis, or acute bacterial pneumonia can be completely reversible over a period of 3 to 6 months upon resolution of endobronchial plugging and infection. This entity is termed Pseudobronchiectasis. Hence, an HRCT should not be performed during an acute pneumonia episode to confirm permanent bronchiectasis; imaging should be deferred for at least 6-12 weeks after clinical resolution."
6. What is Kartagener Syndrome and what is its classic clinical triad?	Kartagener syndrome is a subgroup of Primary Ciliary Dyskinesia (PCD) inherited as an autosomal recessive disorder caused by mutations in outer or inner dynein arm genes (e.g., DNAH5, DNAI1). The classic triad consists of: 1) Situs Inversus Totalis (dextrocardia with inverted abdominal viscera); 2) Chronic Sinusitis with nasal polyposis; and 3) Bronchiectasis.

Clinical Presentation & Bedside Semiology

Question	Answer
1. Describe the characteristic features of sputum in a child with severe bronchiectasis.	Sputum is typically copious, purulent (yellowish-green), and separates into three distinct layers when allowed to stand in a conical cylinder: 1) Top layer: Frothy and mucoid; 2) Middle layer: Turbid, cloudy, watery serous fluid; 3) Bottom layer: Thick, dense, sedimented purulent material composed of polymorphonuclear leukocytes, cellular debris, mucus plugs, and bacterial colonies.
2. Why are crackles in bronchiectasis described as "post-tussive"?	In bronchiectasis, secretions pool in dilated, flaccid bronchi. Auscultating before a cough reveals coarse, low-pitched, bubbling inspiratory crackles. When the child is asked to cough vigorously, secretions are partially sheared and displaced along the bronchial tree, causing the crackles to characteristically change in quality, become crisper, alter in pitch, or shift to a different auscultatory phase or area. This dynamic variability differentiates them from the static crackles of parenchymal consolidation or pulmonary edema.
3. What is the pathophysiology of digital clubbing in suppurative lung disease?	Chronic hypoxemia and endobronchial inflammation lead to platelet clump and megakaryocyte entrapment in distal nail-bed capillary microvasculature, bypassing normal pulmonary capillary fragmentation. Platelet-Derived Growth Factor (PDGF) and Vascular Endothelial Growth Factor (VEGF) are released, inducing periosteal hyperplasia, fibrovascular proliferation, and edema in the subungual connective tissue.
4. How do you distinguish cavernous/amphoric bronchial breathing from tubular bronchial breathing?	Tubular bronchial breathing is high-pitched, harsh, hollow, heard over consolidated lung with patent draining bronchi (e.g., lobar pneumonia). Cavernous bronchial breathing is low-pitched, hollow, and resonance-rich, produced by air vibrating within a large, superficial, empty, dilated cavity or saccular bronchiectasis ($>2-3\text{ cm}$) communicating with an open bronchus. Amphoric breathing is a metallic, high-pitched ringing variant heard over rigid-walled cavities or large superficial pneumothoraces.
5. VIVA TRAP: Why does massive hemoptysis occur in bronchiectasis, and what is its vascular source?	Examiner: "Which blood vessels are responsible for massive hemoptysis in a child with bronchiectasis: the pulmonary arteries or bronchial arteries?" Response: "Sir/ma'am, massive hemoptysis originates from the Bronchial Arteries in $>90\%$ of cases, NOT the pulmonary arteries! Chronic transmural inflammation stimulates intense angiogenesis, causing bronchial arteries (which arise from the high-pressure systemic aorta at $100-120\text{ mmHg}$) to become enormously hypertrophied, tortuous, and thin-walled. Rupture of these high-pressure vessels under coughing stress produces torrential hemoptysis. Pulmonary arterial bleeding is low-pressure and accounts for $<10\%$ of cases."

Diagnostic Workup & Guidelines

Question	Answer
1. What is the gold-standard imaging modality for diagnosing bronchiectasis and what are its key signs?	High-Resolution Computed Tomography (HRCT) of the chest ($1\text{ mm}$ thin collimation slices at $10\text{ mm}$ intervals) is the gold standard. Key signs include: 1) Signet Ring Sign: Internal luminal diameter of the bronchus exceeds the diameter of the adjacent pulmonary artery (Broncho-Arterial Ratio $>1.0$ in children; normal $<0.8$); 2) Tram-Track Sign: Parallel, non-tapering bronchial wall lines visible on longitudinal cuts; 3) Lack of tapering: Bronchial diameter fails to taper over $>2\text{ cm}$ distal to branching; 4) Peripheral visualization: Bronchi visualized within $1\text{ cm}$ of the costal pleura or touching the mediastinal pleura; 5) Mucous plugging and "tree-in-bud" nodularity.
2. What are the diagnostic criteria for Cystic Fibrosis (CF Foundation consensus)?	Diagnosis requires: 1) Clinical features of CF (chronic sinopulmonary disease, gastrointestinal/nutritional abnormalities e.g. meconium ileus, steatorrhea, failure to thrive, obstructive azoospermia) OR positive newborn screening OR history of CF in a sibling; PLUS 2) Evidence of CFTR dysfunction documented by: Sweat Chloride $\ge 60\text{ mmol/L}$ on quantitative pilocarpine iontophoresis on at least two occasions, OR identification of two disease-causing CFTR gene mutations, OR abnormal transepithelial nasal potential difference (NPD).
3. What is the sweat chloride cutoff for diagnosing CF in children?	Normal: $< 30\text{ mmol/L}$; Borderline / Equivocal: $30-59\text{ mmol/L}$; Diagnostic of CF: $\ge 60\text{ mmol/L}$ (when at least $75-100\text{ mg}$ of sweat is collected via Gibson-Cooke pilocarpine iontophoresis).
4. What are the key microbiological pathogens isolated in pediatric bronchiectasis and how do they shift with age?	Early childhood (first 5-7 years): Haemophilus influenzae (non-typeable), Streptococcus pneumoniae, and Staphylococcus aureus. In older children and adolescents with Cystic Fibrosis: colonization shifts to mucoid strains of Pseudomonas aeruginosa, Burkholderia cepacia complex (associated with accelerated lung decline / "cepacia syndrome"), Achromobacter xylosoxidans, and Non-Tuberculous Mycobacteria (M. avium complex, M. abscessus).
5. VIVA TRAP: Can a child have Cystic Fibrosis with a completely normal sweat chloride level?	Examiner: "Can a child have severe CF and still have a sweat chloride of 25 mmol/L?" Response: "Yes, sir/ma'am. Rare 'atypical' or Class IV/V CFTR mutations with residual CFTR channel function (such as $3849+10\text{kb C}\to\text{T}$ or $R117H$) can present with borderline or normal sweat chloride levels. Additionally, severe hypoproteinemic edema in malnourished infants can dilute sweat electrolyte concentrations, producing false-negative results. In such cases, full CFTR gene sequencing and nasal potential difference testing confirm the diagnosis."

Management Protocols & Long-Term Care

Question	Answer
1. What are the core pillars of comprehensive management in pediatric bronchiectasis?	1) Airway Clearance Therapy (ACT): Daily postural drainage, percussion, active cycle of breathing techniques (ACBT), or oscillating positive expiratory pressure (PEP) devices (e.g., Flutter, Acapella); 2) Mucolytics: Inhaled Dornase alfa (recombinant human DNase) and/or nebulized $7\%$ hypertonic saline; 3) Targeted Antimicrobial Therapy: Prompt IV treatment of acute exacerbations and inhaled suppressive antibiotics for chronic Pseudomonas colonization; 4) Anti-inflammatory Therapy: Long-term oral Azithromycin ($10\text{ mg/kg}$ 3 times weekly); 5) Nutritional Support: High-calorie diet ($120-150\%$ RDA), Pancreatic Enzyme Replacement Therapy (PERT), and fat-soluble vitamins; 6) Surgical Resection: Reserved for localized, uniresidual lobe disease refractory to medical management.
2. How does Dornase Alfa (Pulmozyme) work, and when is it contraindicated?	Dornase alfa is recombinant human deoxyribonuclease I (rhDNase). In suppurative airways, dying neutrophils release vast amounts of high-molecular-weight extracellular DNA, causing extreme sputum viscidity. Dornase alfa enzymatically cleaves this extracellular DNA into smaller fragments, rapidly hydrolyzing sputum viscosity and facilitating mucociliary transport. It is indicated in Cystic Fibrosis; however, it is contraindicated in non-CF bronchiectasis because clinical trials demonstrated worse airflow obstruction and increased exacerbation rates.
3. What is the role of long-term macrolide therapy (Azithromycin) in bronchiectasis?	Low-dose Azithromycin ($10\text{ mg/kg}$ 3 times a week, max 250-500 mg/dose) is administered not for direct bactericidal action, but for its immunomodulatory and anti-biofilm properties. It inhibits neutrophil IL-8 and TNF-alpha release, attenuates hypersecretion, disrupts P. aeruginosa alginate biofilm architecture, and significantly reduces annual pulmonary exacerbation rates.
4. What are CFTR Modulators and what are the main classes?	CFTR modulators are small-molecule therapies that directly target the underlying molecular defect of the CFTR protein: 1) Potentiators (e.g., Ivacaftor): Hold the CFTR channel open at the cell surface to increase chloride gating (effective for gating mutations like $G551D$); 2) Correctors (e.g., Lumacaftor, Tezacaftor, Elexacaftor): Assist misfolded CFTR proteins to fold properly and traffic to the cell surface instead of undergoing proteasomal degradation (essential for $\Delta F508$ class II defects). Trikafta (Elexacaftor + Tezacaftor + Ivacaftor) has revolutionized treatment in $>90\%$ of CF patients.
5. What are the strict indications for surgical lobectomy in pediatric bronchiectasis?	Surgery is considered only when: 1) Disease is strictly localized to a single anatomical segment or lobe (confirmed on HRCT); 2) Optimal, aggressive medical therapy and airway clearance for $>1-2\text{ years}$ has failed, with persistent debilitating symptoms; 3) Recurrent life-threatening massive hemoptysis refractory to bronchial artery embolization; 4) Persistent, localized endobronchial obstruction (e.g., missed foreign body or bronchial stenosis); and 5) Adequate pulmonary reserve in the remaining lung fields.